Figure 3.

Distribution of deleterious mutations among the 29 tumors. A gene is considered actionable if linked to targeted therapies approved by Food and Drug Administration. A mutation is classified as deleterious if considered as such by SIFT algorithm or POLYPHEN algorithm. (A) Proportion of tumors with a deleterious mutation on gene considered actionable (blue) and proportion of patients for whom their deleterious mutations could allow inclusion in a clinical trial (purple). (B) Representation of most mutated genes across tumors.